A GLP-1 weight loss program should include a medical eligibility review, prescription only when appropriate, medication access, side-effect monitoring, and nutrition or activity support. The best program depends on your health history, budget, insurance coverage, medication preference, and whether you need brand-name or compounded options from a licensed provider.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is a GLP-1 weight loss program?
A GLP-1 weight loss program is medical care built around prescription medicines that act on glucagon-like peptide-1 pathways. A strong program does more than ship medication: it screens for safety, checks side effects, adjusts the plan over time, and supports food, movement, sleep, and muscle health.
How medical weight loss programs differ from diet-only programs
Diet-only programs focus on calorie targets, food quality, exercise, and behavior skills. Medical weight loss programs may add prescription medication when a clinician finds that the benefits outweigh the risks. FDA labels for chronic weight management medicines also describe use with a reduced-calorie diet and increased physical activity, not medication alone 3 4 5.
Why provider monitoring matters with prescription weight loss medication
Provider monitoring matters because GLP-1 and GIP/GLP-1 medicines can cause gastrointestinal side effects and may be inappropriate for some patients. Labels for semaglutide, tirzepatide, and liraglutide include warnings or precautions around pancreatitis, gallbladder disease, kidney injury related to dehydration, hypoglycemia risk when used with insulin or sulfonylureas, and thyroid C-cell tumor warnings 3 4 5.
Which medications can be part of a GLP-1 weight loss program?
A GLP-1 program may include semaglutide, tirzepatide, liraglutide, or another incretin-based medication depending on the patient and the prescriber. Brand-name drugs have FDA-reviewed labels; compounded formulations are different products prepared by a 503A compounding pharmacy when prescribed and are not FDA-approved.
Semaglutide: Wegovy, Ozempic, Rybelsus, and compounded semaglutide
Semaglutide is a GLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management in eligible adults and some adolescents, while Ozempic and Rybelsus are FDA-approved for type 2 diabetes indications 3 6 7. Chia offers compounded semaglutide injection through licensed-provider review and a state-licensed 503A pharmacy; compounded semaglutide is not FDA-approved and should not be described as the same as Wegovy or Ozempic.
Tirzepatide: Zepbound, Mounjaro, and compounded tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Zepbound is FDA-approved for chronic weight management in eligible adults, while Mounjaro is FDA-approved to improve glycemic control in adults with type 2 diabetes 4 8. Chia offers compounded tirzepatide tablets or injections after licensed-provider review; compounded tirzepatide is not FDA-approved and does not have FDA-evaluated outcomes data.
Liraglutide and other GLP-1 options
Liraglutide is a GLP-1 receptor agonist. Saxenda is FDA-approved for chronic weight management, while Victoza is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes and established cardiovascular disease 5 9. Orforglipron is an investigational oral GLP-1 receptor agonist studied for obesity and type 2 diabetes; it is not an FDA-approved weight-loss drug at this time 10.
GLP-1 tablets vs injections
Most FDA-approved weight-loss GLP-1 options are injections. Oral semaglutide under the Rybelsus label is FDA-approved for type 2 diabetes, not chronic weight management 7. In research, oral agents such as orforglipron have shown weight-loss effects, but side effects like nausea, vomiting, diarrhea, and constipation remain important, and availability depends on regulatory approval 10.
| Medication | Drug class | Common brand context | Weight-loss label status | Common cautions |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Wegovy, Ozempic, Rybelsus; compounded semaglutide is a different, non-FDA-approved product | For brand-name products: Wegovy is FDA-approved for chronic weight management in eligible patients; Ozempic and Rybelsus have type 2 diabetes labels 3 6 7 | Nausea, vomiting, diarrhea, constipation, pancreatitis warnings, gallbladder disease, thyroid C-cell tumor warning 3 |
| Tirzepatide | GIP/GLP-1 receptor agonist | Zepbound, Mounjaro; compounded tirzepatide is a different, non-FDA-approved product | For brand-name products: Zepbound is FDA-approved for chronic weight management in eligible adults; Mounjaro has a type 2 diabetes label 4 8 | Nausea, diarrhea, vomiting, constipation, pancreatitis warnings, gallbladder disease, thyroid C-cell tumor warning 4 |
| Liraglutide | GLP-1 receptor agonist | Saxenda, Victoza | Saxenda is FDA-approved for chronic weight management in eligible patients; Victoza has a type 2 diabetes label 5 9 | Nausea, vomiting, diarrhea, constipation, pancreatitis warnings, gallbladder disease, thyroid C-cell tumor warning 5 |
| Orforglipron | Oral GLP-1 receptor agonist under study | Foundayo has been discussed as a proposed brand name in media and development contexts, but availability depends on approval | Investigational for obesity; not FDA-approved for weight loss at this time 10 | In trials, gastrointestinal side effects were common; long-term real-world safety is still being studied 10 |
Who may qualify for GLP-1 medication for weight loss?
Eligibility depends on BMI, health conditions, medication history, pregnancy plans, and safety risks. A clinician should review the full picture before prescribing.
Common BMI and weight-related condition criteria
FDA labels for chronic weight management commonly include adults with obesity, defined as BMI 30 kg/m² or higher, or adults with overweight, defined as BMI 27 kg/m² or higher, plus at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease risk factors 3 4 5. Some programs also review prediabetes, PCOS, MASH, joint pain, and family history as part of overall risk, but those factors do not replace the label criteria.
Health history factors a clinician may review
A clinician may review current medications, diabetes status, blood pressure, cholesterol, kidney function, liver history, gallbladder history, pancreatitis history, pregnancy plans, prior weight-loss medications, and eating-disorder history. This is important because GLP-1 medicines can change appetite, food intake, hydration, glucose levels, and gastrointestinal symptoms 3 4.
Who may not be a good candidate
People who are pregnant, trying to become pregnant, or breastfeeding may not be candidates. FDA labels also warn against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, often called MEN2 3 4 5. A history of pancreatitis, severe gastrointestinal disease, gallbladder disease, or use of insulin or sulfonylureas may require extra caution or a different plan.
How do GLP-1 programs help with weight loss?
GLP-1 receptor agonists help many people eat less by changing appetite and fullness signals. They also affect insulin, glucagon, and gastric emptying, which is why monitoring side effects and glucose risk matters.
Appetite, fullness, gastric emptying, insulin, and glucagon
GLP-1 medicines activate receptors involved in satiety and appetite regulation. They can increase glucose-dependent insulin secretion, lower glucagon when glucose is high, and slow gastric emptying, especially early in treatment 3 4. These same effects can also lead to nausea, early fullness, reflux, vomiting, diarrhea, or constipation.
Why lifestyle support still matters
Medication does not replace nutrition, activity, sleep, and behavior work. In major semaglutide and tirzepatide trials, participants also received lifestyle intervention, so the trial results reflect medication plus support rather than medication in isolation 1 2.
Muscle loss, protein, and resistance training considerations
Weight loss can include fat mass and lean mass. In a STEP 1 body-composition substudy, semaglutide was associated with large reductions in fat mass and also some lean-mass loss, even though the proportion of lean mass increased because fat loss was larger 11. This is why many clinicians discuss protein intake, resistance training, and safe activity plans, while also watching for nausea or low intake that may make nutrition harder.
How much weight can people lose in GLP-1 programs?
In clinical trials, average weight loss has been meaningful, but it varies by medication, dose studied, adherence, side effects, lifestyle support, and biology. Trial numbers describe the active ingredient as studied, not guaranteed results for any person or for compounded formulations.
What clinical trials show for semaglutide
In STEP 1, adults with overweight or obesity and without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention. Average weight change at 68 weeks was -14.9% with semaglutide versus -2.4% with placebo; nausea and diarrhea were common, and more participants stopped treatment because of gastrointestinal events in the semaglutide group 1. Compounded semaglutide formulations are not FDA-approved and have not been evaluated by FDA for these outcomes.
What clinical trials show for tirzepatide
In SURMOUNT-1, adults with obesity or overweight and without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention. Average weight change at 72 weeks was -15.0%, -19.5%, and -20.9% across those tirzepatide groups versus -3.1% with placebo; nausea, diarrhea, and constipation were common and usually occurred during dose escalation 2. Compounded tirzepatide formulations are not FDA-approved and have not been evaluated by FDA for these outcomes.
Why individual results vary
Individual results vary because appetite response, side effects, adherence, dose tolerance, sleep, stress, medications, hormones, and activity all differ. Some people do not tolerate a medicine well enough to continue, and others may need a different treatment plan. In STEP 4, people who stopped semaglutide after a run-in period regained weight on average, while those who continued lost more, which shows why long-term planning matters 12.
How to think about losing 20 pounds safely
A 20-pound goal means different things for different bodies. For someone starting at 200 pounds, 20 pounds is 10% of body weight; for someone starting at 300 pounds, it is about 6.7%. Guidelines often consider 5% or more weight loss clinically meaningful because it can improve some cardiometabolic risk factors, but side effects, nutrition quality, and muscle preservation matter too 13.
How much do GLP-1 weight loss programs cost?
GLP-1 program cost can include the visit, membership, medication, labs, follow-ups, nutrition support, and supplies. Your final cost depends on whether you use insurance, a brand-name medication, or a compounded medication from a licensed pharmacy.
Visit fees, subscriptions, medication costs, labs, and follow-ups
Some programs bill separate visit fees, lab fees, and medication costs. Others use monthly plans that include provider access and medication. Labs may be useful when a clinician needs to review diabetes risk, kidney function, liver markers, lipids, pregnancy status, or other safety factors, but the right lab plan depends on the person.
Insurance, manufacturer savings cards, and cash-pay pricing
Insurance coverage, prior authorization rules, manufacturer savings-card eligibility, and drug availability vary and can change. Brand-name GLP-1 costs are often very different depending on coverage. Cash-pay programs may be simpler to understand, but you still need a real clinician review and a clear pharmacy source.
Brand-name vs compounded medication cost considerations
Brand-name drugs such as Wegovy and Zepbound have FDA-reviewed labels for chronic weight management in eligible patients 3 4. Compounded medications are prepared for a patient by a state-licensed 503A pharmacy when prescribed, are not FDA-approved, and do not have FDA-reviewed efficacy data. The safety question is not just brand versus compounded; it is whether the program uses licensed clinicians, clear prescriptions, and licensed pharmacy partners rather than no-prescription “research” sellers.
How should you compare GLP-1 weight loss programs?
Compare programs by medical quality first: clinician review, eligibility rules, pharmacy transparency, side-effect support, follow-up access, and cost clarity. A cheaper program is not helpful if it skips safety screening or hides where medication comes from.
| Program type | What it may include | Potential fit | Questions to ask |
|---|---|---|---|
| Hospital or academic weight-management clinic | In-person exams, labs, dietitians, obesity medicine clinicians, and access to other services | People with complex medical history, diabetes, sleep apnea, MASH, PCOS, or surgical considerations | How long is the wait, what is covered by insurance, and who manages dose changes? |
| Retail clinic or pharmacy-linked program | Basic screening, virtual or in-person visits, and prescription routing | People who want a familiar retail access point | Is there ongoing clinician follow-up, and what pharmacy fills the prescription? |
| App-based coaching program | Nutrition coaching, habit tools, weight tracking, and sometimes medication referral | People who mainly want behavior support and accountability | Is prescribing included, separate, or referred out? |
| Telehealth prescribing model, including Chia | Online intake, licensed-provider review, prescription when appropriate, compounded medication access, and home delivery | People who want remote care and clear access to compounded semaglutide or tirzepatide through a licensed pathway | Which forms are offered, what does the price include, and how do you message the care team? |
Questions to ask before signing up
- Will a licensed clinician review my health history before any prescription is considered?
- Which medication options are available, and are they brand-name, compounded, or both?
- If compounded medication is used, is it prepared by a state-licensed 503A compounding pharmacy?
- What side effects should I report, and how quickly can I reach the care team?
- Are labs, follow-up visits, supplies, and shipping included in the listed price?
- What happens if I have nausea, vomiting, constipation, diarrhea, low appetite, or signs of dehydration?
- How does the program support protein intake, resistance training, and long-term maintenance?
Red flags: guaranteed prescriptions, no clinician review, unclear pharmacy source
Be careful with any program that guarantees a prescription before reviewing your health history. Also avoid no-prescription sellers, unclear pharmacy sources, “research chemical” GLP-1 products, or programs that cannot explain side-effect support. FDA has warned that unapproved GLP-1 products can pose risks when quality, ingredients, dosing, or oversight are unclear 14.
3-min quiz
Compare your options with a licensed-provider review
At Chia, eligible patients may be prescribed compounded semaglutide injection or compounded tirzepatide tablets or injections after an online intake and licensed US provider review. A prescription is not guaranteed. Compounded drugs are not FDA-approved and are prepared by state-licensed 503A pharmacies when prescribed.
GLP-1 weight loss treatment at Chia: semaglutide or tirzepatide options
At Chia, we offer a 100% online path for eligible patients considering compounded GLP-1 treatment. Our providers review your health information and prescribe only when clinically appropriate.
Chia’s online intake, licensed provider review, and home delivery model
Chia starts with a short health questionnaire. A licensed US provider reviews it, considers your goals and medical history, and decides whether treatment is appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door.
Compounded semaglutide injection through Chia
Chia offers compounded semaglutide injection, with plans currently starting at $249/mo. Microdosing plans are available when clinically appropriate. Dosing is provider-guided and adjusted over time; we do not expect patients to manage dose changes on their own.
Compounded tirzepatide tablets or injections through Chia
Chia offers compounded tirzepatide as tablets, with plans currently starting at $249/mo, and injections, with plans currently starting at $299/mo. Microdosing plans are available when clinically appropriate, with provider-guided adjustments and portal messaging between visits.
| Chia option | Forms offered | Current starting price | May fit patients who prefer |
|---|---|---|---|
| Compounded semaglutide | Injection | From $249/mo | A once-weekly injectable GLP-1 plan reviewed by a licensed provider |
| Compounded tirzepatide | Tablets | From $249/mo | A non-injection form when a provider finds it appropriate |
| Compounded tirzepatide | Injection | From $299/mo | An injectable GIP/GLP-1 plan reviewed by a licensed provider |
Weight + Energy and Weight + Muscle protocol options
Some patients ask about broader longevity support while losing weight. Chia offers Weight + Energy, which combines NAD+ injection with a choice of GLP-1 and currently starts at $309/mo, and Weight + Muscle, which combines Sermorelin injection with a choice of GLP-1 and currently starts at $329/mo. These protocols still require provider review, and a prescription is not guaranteed.
What happens after you start a GLP-1 program?
After starting, a good program follows your symptoms, weight trend, nutrition, medication tolerance, and safety risks. Dose changes should be clinician-guided, not self-directed.
Follow-up, dose adjustments, and side-effect check-ins
FDA labels for Wegovy and Zepbound describe gradual dose escalation schedules, such as Wegovy starting at 0.25 mg once weekly for the first 4 weeks before stepwise increases, and Zepbound starting at 2.5 mg once weekly for 4 weeks before increasing to 5 mg once weekly 3 4. Those label schedules are not instructions for you; your own plan should come from your prescriber. Follow-up is also when a clinician reviews nausea, vomiting, diarrhea, constipation, hydration, glucose risk, and whether the plan is still safe.
When a clinician may change or stop treatment
A clinician may slow changes, adjust the plan, pause treatment, or stop medication if side effects are severe, if warning symptoms appear, if pregnancy occurs, if another medication creates risk, or if the benefit is not enough. Labels advise patients to seek medical attention for symptoms that could suggest pancreatitis or gallbladder disease, such as severe abdominal pain 3 4.
Long-term maintenance and what may happen after stopping medication
Obesity is a chronic condition for many people, so maintenance planning matters. In the STEP 1 extension, participants regained about two-thirds of prior weight loss during the year after semaglutide withdrawal, showing that stopping medication can be followed by regain in many patients 15. Long-term plans should also consider side effects, cost, access, muscle health, and personal goals.
FAQ about GLP-1 weight loss programs
The best program is the one that matches your medical history, budget, medication access, side-effect needs, and follow-up preferences. Look for licensed clinician review, clear pharmacy sourcing, realistic expectations, and support for nutrition, activity, and long-term maintenance.
The cheapest option depends on insurance coverage, savings-card eligibility, visit fees, lab costs, and whether the medication is brand-name or compounded. A low monthly price is not enough by itself; the program should still include clinician screening, side-effect support, and a clear licensed pharmacy source.
Yes, some telehealth programs can prescribe GLP-1 medication online after a licensed clinician reviews your health history and finds treatment appropriate. A prescription should never be guaranteed before a medical review.
No. Compounded medications are not FDA-approved, and FDA does not evaluate them for safety, effectiveness, or quality before dispensing. When prescribed, they should come through a licensed clinician and a state-licensed 503A compounding pharmacy.
It depends on the specific drug and study. Most FDA-approved chronic weight-management GLP-1 options are injections. Oral semaglutide is FDA-approved for type 2 diabetes, not chronic weight management, and newer oral GLP-1 drugs are still being studied.
There is no safe universal timeline. A 20-pound loss may be a small or large percentage of body weight depending on where someone starts. Clinicians usually focus on steady progress, side effects, protein intake, resistance training, and whether the plan is safe to continue.
Some do, and some do not. Even when formal coaching is not included, a good medical program should still discuss food quality, protein intake, hydration, constipation prevention, activity, and muscle preservation.
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. Chia still requires an online health intake and licensed US provider review, and a prescription is not guaranteed.
3-min quiz
Start your online GLP-1 eligibility review
If you are comparing GLP-1 programs, Chia can review whether compounded semaglutide, compounded tirzepatide, or a protocol such as Weight + Energy or Weight + Muscle may fit your goals. A licensed provider prescribes only when clinically appropriate, and treatment is shipped to your door when prescribed.
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 3.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 4.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2025.
- 5.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information. 2023.
- 6.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
- 7.U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets prescribing information. 2024.
- 8.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2024.
- 9.U.S. Food and Drug Administration. Victoza (liraglutide) injection prescribing information. 2023.
- 10.Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine. 2023.
- 11.Wilding JPH, Batterham RL, Davies M, et al. Effects of semaglutide 2.4 mg on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021.
- 12.Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
- 13.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014.
- 14.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. 2025.
- 15.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
